Skip to main
PDSB
PDSB logo

PDSB Stock Forecast & Price Target

PDSB Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PDS Biotechnology's proprietary Versamune platform has demonstrated promising clinical outcomes, including a 100% clearance rate of HPV16-positive cancer cells in patients receiving combination therapy, compared to just 50% in the control group, highlighting its efficacy. The reported two-year recurrence-free survival rate of 93% for patients with undetectable HPV16 ctDNA indicates a significant potential for improved patient outcomes and positions the company favorably for its upcoming Phase 3 trial. Additionally, the proprietary technology's ability to enhance T-cell targeting against specific proteins positions PDS Biotechnology as a notable player in the oncology landscape, offering substantial commercial opportunities and value for investors.

Bears say

PDS Biotechnology Corp's outlook is clouded by the potential for failed or inconclusive clinical trials, which could severely hinder the company's ability to advance its drug development efforts. Additionally, the company faces challenges in securing sufficient funding, a critical factor for continuing progress in its pipeline of cancer treatments. Moreover, the correlation of MUC1 overexpression with poor patient prognosis and limited survival outcomes, coupled with existing standard of care options only providing a median overall survival of approximately 18 months, further underscores the risks associated with the firm's clinical efficacy and market position.

PDSB has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PDS Biotechnology Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PDS Biotechnology Corporation (PDSB) Forecast

Analysts have given PDSB a Strong Buy based on their latest research and market trends.

According to 6 analysts, PDSB has a Strong Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PDS Biotechnology Corporation (PDSB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.